MHRA bans OTC sale of codeine after recreational abuse reports

21 Feb 2024
www.pharmaceutical-technology.com
Phase 3Clinical Result
MHRA bans OTC sale of codeine after recreational abuse reports
Preview
Source: Pharmaceutical Technology
Recent safety information has shown that codeine linctus is being misused recreationally for its opioid effects, instead of its intended use as a cough medicine. Credit: New Africa via Shutterstock.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced that codeine linctus is to be reclassified as a prescription-only medicine due to the risk of abuse, dependency and overdose.
This follows a consultation launched by the MHRA in July 2023 after Yellow Card reports indicated instances of the medicine being abused, rather than for its intended use as a cough suppressant. The consultation ran for four weeks, closing on 15 August 2023.
Recent safety information indicates that codeine linctus is being misused recreationally for its opioid effects, instead of its intended use as a cough medicine. This poses a serious risk of addiction and potentially fatal overdose.
Codeine linctus is an oral solution intended to treat adults with dry coughs. Opioid medications bind to specific receptors in the brain that reduce the perception of pain while also producing feelings of euphoria, relaxation, and sedation, making the drugs addictive, and potentially leading to dependence with prolonged use.
Data from the Office for National Statistics revealed an increase in the annual number of deaths where codeine was involved from 88 deaths in 2011 to 200 deaths in 2021.
See Also:MT-110 by Myosin Therapeutics for Substance (Drug) Abuse: Likelihood of Approval
MHRA bans OTC sale of codeine after recreational abuse reports
Preview
Source: Pharmaceutical Technology
Xolair amplifies reach after FDA approval for treating food allergies
MHRA bans OTC sale of codeine after recreational abuse reports
Preview
Source: Pharmaceutical Technology
In July 2023, the MHRA revealed a three-year corporate plan to create a quicker and more predictable legal landscape. The plan’s emphasis on the maintenance of public trust includes several initiatives, which include a pilot of public hearings on major safety issues throughout 2024 and 2025.
In the announcement accompanying the reclassification, the MHRA’s chief safety officer Alison Cave said: “Patient safety is our top priority. Codeine linctus is an effective medicine for long-term dry cough, but as it is an opioid, its misuse and abuse can have major health consequences.”
In the US, an ongoing opioid crisis demands alternatives to addictive pain medications. While some people are addicted to illicit opioids such as heroin, many are addicted to legal drugs such as codeine. Earlier this year, Vertex Pharmaceuticals announced plans to submit a new drug application for its non-opioid pain medication to the US Food and Drug Administration following positive results from a Phase III programme, marking a significant development in the field.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.